The 6 patients receiving TB4 experienced a 35.1% decrease in eye discomfort and a 59.1% reduction in total corneal fluorescein staining, relative to the control group [35]
While Balfaxar met the primary endpoint of hemostatic efficacy in a Phase III study and was non-inferior to the comparator, Kcentra, fatal and non-fatal arterial and venous thromboembolic complications were observed in clinical trials and post-marketing studies, and healthcare providers are advised to monitor patients for signs of thromboembolic events
The peptide comes in a lyophilized (freeze-dried) form, which needs to be reconstituted with sterile water
Eur J Pharmacol 379(1):1931 Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D et al (1999) A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinsons disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine